167 related articles for article (PubMed ID: 29920736)
1. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.
Tachibana M; Yamamura N; Atiee GJ; Hsu C; Warren V; He L; Dishy V; Zahir H
Br J Clin Pharmacol; 2018 Oct; 84(10):2317-2324. PubMed ID: 29920736
[TBL] [Abstract][Full Text] [Related]
2. Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study
.
Dow J; Currie A; He L; Zaidi F; Zahir H
Int J Clin Pharmacol Ther; 2018 Oct; 56(10):451-458. PubMed ID: 30049303
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
[TBL] [Abstract][Full Text] [Related]
4. Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers.
Zhang YF; Dai XJ; Yang Y; Chen XY; Wang T; Tang YB; Tsai CY; Chang LW; Chang YT; Zhong DF
Drug Des Devel Ther; 2016; 10():357-70. PubMed ID: 26855561
[TBL] [Abstract][Full Text] [Related]
5. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
Brown K; Mendell J; Ohwada S; Hsu C; He L; Warren V; Dishy V; Zahir H
Pharmacol Res Perspect; 2018 Oct; 6(5):e00418. PubMed ID: 30151212
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/probenecid (333 mg): a randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers.
Wu H; Liu M; Wang S; Feng W; Yao W; Zhao H; Wei M
Clin Ther; 2010 Mar; 32(3):597-606. PubMed ID: 20399996
[TBL] [Abstract][Full Text] [Related]
9. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir.
De Bony F; Tod M; Bidault R; On NT; Posner J; Rolan P
Antimicrob Agents Chemother; 2002 Feb; 46(2):458-63. PubMed ID: 11796358
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.
Jansen M; Mendell J; Currie A; Dow J; He L; Merante D; Dishy V; Ishizuka H; Zahir H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):597-612. PubMed ID: 29870596
[TBL] [Abstract][Full Text] [Related]
11. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
[TBL] [Abstract][Full Text] [Related]
12. The effect of probenecid on the renal elimination of cimetidine.
Gisclon LG; Boyd RA; Williams RL; Giacomini KM
Clin Pharmacol Ther; 1989 Apr; 45(4):444-52. PubMed ID: 2702802
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment.
Kato M; Tajima N; Shimizu T; Sugihara M; Furihata K; Harada K; Ishizuka H
J Clin Pharmacol; 2018 Jan; 58(1):57-63. PubMed ID: 28834546
[TBL] [Abstract][Full Text] [Related]
14. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.
Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
J Diabetes Investig; 2019 Sep; 10(5):1299-1306. PubMed ID: 30672128
[TBL] [Abstract][Full Text] [Related]
15. Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator.
Weiss HM; Langenickel T; Cain M; Kulkarni S; Shah B; Vemula J; Rahmanzadeh G; Poller B
Drug Metab Dispos; 2021 May; 49(5):389-394. PubMed ID: 33632715
[TBL] [Abstract][Full Text] [Related]
16. Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin.
Duchin K; Senaldi G; Warren V; Marbury T; Lasseter K; Zahir H
Clin Drug Investig; 2018 Nov; 38(11):1001-1009. PubMed ID: 30171457
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
Vinik A; Rosenstock J; Sharma U; Feins K; Hsu C; Merante D;
Diabetes Care; 2014 Dec; 37(12):3253-61. PubMed ID: 25231896
[TBL] [Abstract][Full Text] [Related]
18. An interaction study with cimetidine and the new angiotensin II antagonist valsartan.
Schmidt EK; Antonin KH; Flesch G; Racine-Poon A
Eur J Clin Pharmacol; 1998 Feb; 53(6):451-8. PubMed ID: 9551704
[TBL] [Abstract][Full Text] [Related]
19. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans.
Shiga T; Hashiguchi M; Urae A; Kasanuki H; Rikihisa T
Clin Pharmacol Ther; 2000 Mar; 67(3):222-8. PubMed ID: 10741624
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin.
Yin OQ; Merante D; Truitt K; Miller R
J Clin Pharmacol; 2016 Feb; 56(2):203-12. PubMed ID: 26138993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
